Skip to main content
SpringerLink
Log in

Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

  • Chapter
  • First Online:
ASPC Manual of Preventive Cardiology

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 768 Accesses

Abstract

Chronic kidney disease (CKD) is a common condition affecting a roughly estimated 400–850 million of the world’s population, primarily older adults. A variety of cardiovascular diseases (CVD) are common in this population, mostly due to similarity of risk factors, such as age, diabetes, hypertension, obesity, and dyslipidemia. But CKD also evokes a unique pathophysiology that contributes to the prevalence of CVD in this population. Primary prevention of CKD is possible and might contribute to a lower burden of CVD. Secondary prevention of progression of CKD to advanced stages, including end-stage kidney disease (ESKD), through early detection and aggressive management might also reduce the burden of CVD. Opportunities for primary and secondary prevention of the various forms of CVD seen in mild to moderate CKD will be the focus of this review, rather than treatment of CVD seen in association with advanced CKD (ESKD), treated by dialysis or transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kidney Disease Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines for the evaluation and management of chronic kidney diseases. Kidney Int Suppl. 2013; 3:1–150.

    Google Scholar 

  2. Vallianou NG, Mitesh S, Gkogkou A, et al. Chronic kidney disease and cardiovascular disease: is there any relationship? Curr Cardiol Rev. 2019;15:55–63.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, Marwick TH, Conference Participants. Chronic kidney disease and coronary artery disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74:1823–38.

    Article  CAS  PubMed  Google Scholar 

  4. Ali S, Dave N, Virani SS, Navaneethan SD. Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep. 2019;21:32.

    Article  PubMed  Google Scholar 

  5. Thomas B, Matsushita K, Abate KH, Al-Aly Z, Ärnlöv J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barregård L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schöttker B, Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi M, Forouzanfar MH, Murray CJL, Coresh J, Vos T, Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, Global Burden of Disease Genitourinary Expert Group. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28:2167–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Marx N, Noels H, Jankowski J, Floege J, Fliser D, Böhm M. Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol. 2018;107(Suppl 2):120–6.

    Article  PubMed  Google Scholar 

  7. United States Renal Data System. 2019 annual data report: Atlas of chronic kidney disease and end-stage renal failure in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease; 2019.

    Google Scholar 

  8. United States Renal Data System. 2018 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Chapter 4: Cardiovascular disease in patients with CKD. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018.

    Google Scholar 

  9. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One. 2016;11(7):e158765.

    Article  Google Scholar 

  10. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.

    Article  Google Scholar 

  11. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.

    Article  CAS  PubMed  Google Scholar 

  12. Delanaye P, Jager KJ, Bökenkamp A, Christensson A, Dubourg L, Eriksen BO, Gaillard F, Gambaro G, van der Giet M, Glassock RJ, Indridason OS, van Londen M, Mariat C, Melsom T, Moranne O, Nordin G, Palsson R, Pottel H, Rule AD, Schaeffner E, Taal MW, White C, Grubb A, van den Brand JAJG. CKD: a call for an age-adapted definition. J Am Soc Nephrol. 2019;30:1785–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Delanaye P, Glassock RJ, De Broe ME. Epidemiology of chronic kidney disease: think (at least) twice! Clin Kidney J. 2017;10:370–4.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13:104–14.

    Article  CAS  PubMed  Google Scholar 

  15. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504–11.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Matsushita K, van der Velde M, Astor BC, et al, for the CKD Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.

    Google Scholar 

  17. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  CAS  PubMed  Google Scholar 

  18. Pun PH, et al. The interplay between chronic kidney disease, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis. 2014;21(6):480–8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;15:340.

    Article  PubMed  Google Scholar 

  20. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14.

    Article  PubMed  Google Scholar 

  21. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2006;151:492–500.

    Article  PubMed  Google Scholar 

  22. Bundy JD, Chen J, Yang W, et al., for the CRIC Study Investigators. Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: the CRIC study. Atherosclerosis. 2018;271:53–60.

    Google Scholar 

  23. Go AS, Bansal N, Chandra M, et al., for the ADVANCE Study Investigators. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J Am Coll Cardiol. 2011;58:1600–7.

    Google Scholar 

  24. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk In Communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307–15.

    Article  CAS  PubMed  Google Scholar 

  25. He J, Shlipak M, Anderson A, et al. Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) study. J Am Heart Assoc. 2017;6. pii: e005336.

    Google Scholar 

  26. Smith DH, Thorp ML, Gurwitz JH, Mcmanus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013;6:333–42.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.

    Article  PubMed  Google Scholar 

  28. Marwick TH, Amann K, et al. Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;96:836–49.

    Article  PubMed  Google Scholar 

  29. Samad Z, Sivak JA, Phelan M, et al. Prevalence and outcomes of left-sided valvular heart disease associated with chronic kidney disease. J Am Heart Assoc. 2017;6(10): pii: e006044.

    Google Scholar 

  30. Guerraty MA, Chai B, Hsu JY, et al. Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol. 2015;115:1281–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2007;50:412–20.

    Article  CAS  PubMed  Google Scholar 

  32. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ. 2010;341:c4249.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Lee M, Saver JL, Chang KH, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2010;30:464–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int. 2003;64:610–5.

    Article  PubMed  Google Scholar 

  35. O’Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation. 2004;109(3):320–3.

    Article  PubMed  Google Scholar 

  36. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk In Communities (ARIC) study. J Am Soc Nephrol. 2007;18:629–36.

    Article  PubMed  Google Scholar 

  37. Wang GJ, Shaw PA, Townsend RR, Anderson AH, Xie D, Wang X, Nessel LC, Mohler ER, Sozio SM, Jaar BG, et al; for the CRIC Study Investigators. Sex differences in the incidence of peripheral artery disease in the Chronic Renal Insufficiency Cohort. Circ Cardiovasc Qual Outcomes. 2016;9:S86–93.

    Google Scholar 

  38. Wu CK, Yang CY, Tsai CT, et al. Association of low glomerular filtration rate and albuminuria with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis. 2009;209(1):230–4.

    Article  PubMed  CAS  Google Scholar 

  39. Wattanakit K, Folsom AR, Criqui MH, et al. Albuminuria and peripheral arterial disease: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2008;201(1):212–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI, Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159:1102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 2011;123:2946–53.

    Article  PubMed  PubMed Central  Google Scholar 

  42. McManus DD, Corteville DCM, Shlipak MG, Whooley MA, Ix JH. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104:1551–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  PubMed  Google Scholar 

  44. Carrero JJ, Trevisan M, Sood MM, Bárány P, Xu H, Evans M, Friberg L, Szummer K. Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Clin J Am Soc Nephrol. 2018;13(9):1314–20.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Mace-Brickman T, Eddeen AB, Carrero JJ, Mark PB, Molnar AO, Lam NN, Zimmerman D, Harel Z, Sood MM. The risk of stroke and stroke type in patients with atrial fibrillation and chronic kidney disease. Can J Kidney Health Dis. 2019;6:1–9.

    Article  Google Scholar 

  46. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol. 2012;23:1929–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006;98:485–90.

    Article  PubMed  Google Scholar 

  48. Afshinnia F, Pennathur S. Lipids and cardiovascular risk with CKD. Clin J Am Soc Nephrol. 2020;15(1):5–7.

    Article  PubMed  Google Scholar 

  49. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz M, Lewis JA, Randall OS, Hebert L, Wright JT Jr, Kendrick CA, Gassman J, Bakris G, Kopple JD, Appel LJ, African-American Study of Kidney Disease, and Hypertension Study Group. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010;21:2131–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Moradi H, Vaziri ND. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed). 2018;23:146–61.

    Article  CAS  Google Scholar 

  51. Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH, SHARP Collaborative Group. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol. 2020;15(1):47–60.

    Article  CAS  PubMed  Google Scholar 

  52. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H. Inverse association between serum non-high-density lipoprotein cholesterol levels and mortality in patients undergoing incident hemodialysis. J Am Heart Assoc. 2018;7(12):e009096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120–31.

    Article  PubMed  Google Scholar 

  55. Qian Q. Salt, water and nephron: mechanisms of action and link to hypertension and chronic kidney disease. Nephrology (Carlton). 2018;23 Suppl 4:44–9.

    Article  CAS  Google Scholar 

  56. Campese VM. Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014;34:571–6.

    Article  CAS  PubMed  Google Scholar 

  57. Zoccali C, London G. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant. 2015;3:352–7.

    Article  CAS  Google Scholar 

  58. Kassem H, Chatila K. Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how? Curr Opin Nephrol Hypertens. 2020;29:258–63.

    Article  PubMed  Google Scholar 

  59. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009;4:755–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15 Suppl 1:S77–80.

    Article  PubMed  Google Scholar 

  61. Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, Holmes DT, Madore F, Clase CM, Rigatto C, Levin A, CanPREDDICT Investigators. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int. 2016;89:1144–52.

    Article  CAS  PubMed  Google Scholar 

  62. Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018;10(1). pii: E33.

    Google Scholar 

  63. Gao S, Xu J, Zhang S, Jin J. Meta-analysis of the association between fibroblast growth factor 23 and mortality and cardiovascular events in hemodialysis patients. Blood Purif. 2019;47 Suppl 1:24–30.

    Article  PubMed  CAS  Google Scholar 

  64. Liu Q, Zhu LJ, Waaga-Gasser AM, Ding Y, Cao M, Jadhav SJ, Kirollos S, Shekar PS, Padera RF, Chang YC, Xu X, Zeisberg EM, Charytan DM, Hsiao LL. The axis of local cardiac endogenous Klotho-TGF-β1-Wnt signaling mediates cardiac fibrosis in human. J Mol Cell Cardiol. 2019;136:113–24.

    Article  CAS  PubMed  Google Scholar 

  65. Böckmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer DC, Heineke J, Haffner D, Leifheit-Nestler M. FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis. Int J Mol Sci. 2019;20(18). pii: E4634.

    Google Scholar 

  66. Tomaschitz A, Piecha G, Ritz E, Meinitzer A, Haas J, Pieske B, Wiecek A, Rus-Machan J, Toplak H, März W, Verheyen N, Gaksch M, Amrein K, Kraigher-Krainer E, Fahrleitner-Pammer A, Pilz S. Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications. Clin Exp Hypertens. 2015;37(2):108–15.

    Article  CAS  PubMed  Google Scholar 

  67. Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract. 2017;133:124–30.

    Article  CAS  PubMed  Google Scholar 

  68. Bonakdaran S, Nejad AF, Abdol-Reza V, Hatefi A, Shakeri M. Impact of oral 1,25-dihydroxy vitamin D (calcitriol) replacement therapy on coronary artery risk factors in type 2 diabetic patients. Endocr Metab Immune Disord Drug Targets. 2013;13(4):295–300.

    Article  CAS  PubMed  Google Scholar 

  69. Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal syndrome and the role of the bone-mineral axis and anemia. Am J Kidney Dis. 2015;66:196–205.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704–14.

    Article  CAS  PubMed  Google Scholar 

  71. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:2180373.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124:139–52.

    Article  CAS  Google Scholar 

  73. Feingold KR, Grunfeld C. Effect of inflammation on HDL structure and function. Curr Opin Lipidol. 2016;27:521–30.

    Article  CAS  PubMed  Google Scholar 

  74. Edmonston DL, Pun PH. Coronary artery disease in chronic kidney disease: highlights for a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97:642–4.

    Article  PubMed  Google Scholar 

  75. Warnock DG, Delanaye P, Glassock RJ. Risks for all-cause mortality: stratified by age, estimated glomerular filtration rate and albuminuria. Nephron. 2017;136(4):292–7.

    Article  PubMed  Google Scholar 

  76. Malmgren L, McGuigan FE, Berglundh S, Westman K, Christensson A, Åkesson K. Declining estimated glomerular filtration rate and its association with mortality and comorbidity over 10 years in elderly women. Nephron. 2015;130:245–55.

    Article  PubMed  Google Scholar 

  77. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008;23:3851–8.

    Article  CAS  PubMed  Google Scholar 

  78. Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol. 2002;18(5):525–35.

    CAS  PubMed  Google Scholar 

  79. Nerpin E, Ingelsson E, Risérus U, Sundström J, Larsson A, Jobs E, Jobs M, Hallan S, Zethelius B, Berglund L, Basu S, Arnlöv J. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant. 2011;26(9):2820–7.

    Article  PubMed  Google Scholar 

  80. Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol. 2011;22:795–7.

    Article  PubMed  Google Scholar 

  81. Turin TC, Jun M, James MT, Tonelli M, Coresh J, Manns BJ, Hemmelgarn BR. Magnitude of rate of change in kidney function and future risk of cardiovascular events. Int J Cardiol. 2016;202:657–65.

    Article  PubMed  Google Scholar 

  82. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF, ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154:310–8.

    Article  PubMed  Google Scholar 

  83. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J, Chronic Kidney Disease Prognosis Consortium. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308(22):2349–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.

    Article  PubMed  PubMed Central  Google Scholar 

  85. van Staa TP, Gulliford M, Ng ES, Goldacre B, Smeeth L. Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? PLoS One. 2014;9(10):e106455.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Melsom T, Fuskevåg OM, Mathisen UD, Strand H, Schei J, Jenssen T, Solbu M, Eriksen BO. Estimated GFR is biased by non-traditional cardiovascular risk factors. Am J Nephrol. 2015;41(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  87. Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton). 2008;13(8):667–71.

    Article  Google Scholar 

  88. Balla S, Nusair MB, Alpert MA. Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. Curr Opin Pharmacol. 2013;13(2):192–9.

    Article  CAS  PubMed  Google Scholar 

  89. Inrig JK, Gillespie BS, Patel UD, Briley LP, She L, Easton JD, Topol E, Szczech LA. Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2007;2:1215–22.

    Article  PubMed  Google Scholar 

  90. Matsushita K, Sang Y, Ballew SH, Astor BC, Hoogeveen RC, Solomon SD, Ballantyne CM, Woodward M, Coresh J. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014;34:1770–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT Jr, Wolf M, He J, CRIC Investigators. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol. 2017;2:635–43.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–83.

    Article  CAS  PubMed  Google Scholar 

  93. Cano-Megías M, Guisado-Vasco P, Bouarich H, de Arriba-de la Fuente G, de Sequera-Ortiz P, Álvarez-Sanz C, Rodríguez-Puyol D. Coronary calcification as a predictor of cardiovascular mortality in advanced chronic kidney disease: a prospective long-term follow-up study. BMC Nephrol. 2019;20:188.

    Google Scholar 

  94. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4 Suppl 1:S79–91.

    Article  PubMed  Google Scholar 

  95. Tripepi G, D’Arrigo G, Mallamaci F, London G, Tangri N, Hsu JY, Feldman H, Zoccali C. Nephrol dial transplant. Prognostic values of left ventricular mass index in chronic kidney disease patients. 2019. [Epub ahead of print].

    Google Scholar 

  96. Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377:1765–76.

    Article  CAS  PubMed  Google Scholar 

  97. Qian F, Riddle MC, Wylie-Rosett J, Hu FB. Red and processed meats and health risks: how strong is the evidence? Diabetes Care. 2020;43:265–71.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, Landman J, Kalantar-Zadeh K. Current management of patients with acquired solitary kidney. Kidney Int Rep. 2019;4(9):1205–18.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Kamper AL, Strandgaard S. Long-term effects of high-protein diets on renal function. Annu Rev Nutr. 2017;37:347–69.

    Article  CAS  PubMed  Google Scholar 

  100. Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. A combination of healthy lifestyle factors is associated with a decreased incidence of chronic kidney disease: a population-based cohort study. Hypertens Res. 2013;36(4):328–33.

    Article  PubMed  Google Scholar 

  101. Chang AR, Lóser M, Malhotra R, Appel LJ. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol. 2019;14(1):161–9.

    Article  CAS  PubMed  Google Scholar 

  102. Briasoulis A, Bakris GL. The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013;83(1):20–2.

    Article  CAS  PubMed  Google Scholar 

  103. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  CAS  Google Scholar 

  104. Chang TI, Lim H, Park CH, Rhee CM, Moradi H, Kalantar-Zadeh K, Kang EW, Kang SW, Han SH. Associations of systolic blood pressure with incident CKD G3-G5: a Cohort Study of South Korean adults. Am J Kidney Dis. 2020;15. [EPub ahead of print].

    Google Scholar 

  105. Guerrot D, Humalda JK. Blood pressure targets in chronic kidney disease: an update on the evidence. Curr Opin Nephrol Hypertens. 2020;29(3):327–32.

    Article  PubMed  Google Scholar 

  106. Chiang HP, Chiu YW, Lee JJ, Hung CC, Hwang SJ, Chen HC. Blood pressure modifies outcomes in patients with stage 3 to 5 chronic kidney disease. Kidney Int. 2020;97(2):402–13.

    Article  PubMed  Google Scholar 

  107. Covic A, Apetrii M, Goldsmith D, Kanbay M. SPRINT: the study nephrologists might take with a grain of salt. J Clin Hypertens (Greenwich). 2016;18(11):1185–8.

    Article  Google Scholar 

  108. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  PubMed  Google Scholar 

  109. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G, REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939–46.

    Article  PubMed  Google Scholar 

  110. Ameh OI, Ekrikpo UE, Kengne AP. Preventing CKD in low- and middle-income countries: a call for urgent action. Kidney Int Rep. 2020;5:255–62.

    Article  PubMed  Google Scholar 

  111. Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in developed countries. Kidney Int Rep. 2020;5:263–77.

    Article  PubMed  Google Scholar 

  112. Blum MF, Surapaneni A, Stewart JD, Liao D, Yanosky JD, Whitsel EA, Power MC, Grams ME. Particulate matter and albuminuria, glomerular filtration rate, and incident CKD. Clin J Am Soc Nephrol. 2020;15:311–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11:264–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008;3:1563–8.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156:570–81.

    Article  PubMed  Google Scholar 

  116. Moyer VA, U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:567–70.

    Article  PubMed  Google Scholar 

  117. Katsiki N, Banach M, Mikhailidis DP. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch Med Sci. 2019;15:1357–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012;380:783–5.

    Article  PubMed  Google Scholar 

  119. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

    Article  CAS  PubMed  Google Scholar 

  120. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.

    Article  CAS  PubMed  Google Scholar 

  121. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–8.

    Article  CAS  PubMed  Google Scholar 

  122. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.

    Article  CAS  PubMed  Google Scholar 

  123. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.

    Article  CAS  PubMed  Google Scholar 

  124. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy. 2017;37:401–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.

    Article  CAS  PubMed  Google Scholar 

  126. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    Article  PubMed  CAS  Google Scholar 

  127. Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138:1505–14.

    Article  CAS  PubMed  Google Scholar 

  128. Aggarwal R, Steinkamp J, Chiu N, Petrie B, Mirzan H. Intensive blood pressure targets for diabetic and other high-risk populations: a pooled individual patient data analysis. Hypertension. 2018;71:833–9.

    Article  CAS  PubMed  Google Scholar 

  129. Whelton PK, et al. ACC/AHA guidelines for prevention, detection, evaluation, management of high blood pressure in adults. Circulation. 2018;138:e489–594.

    Google Scholar 

  130. Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS, Beta-Blockers in Heart Failure Collaborative Group. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019;74:2893–904.

    Article  PubMed  Google Scholar 

  131. Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin has a dose-dependent beneficial effect on kidney function and associated cardiovascular outcomes: post hoc analysis of 6 double-blind randomized controlled trials. J Am Heart Assoc. 2019;8(9):e010827.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381:1557–67.

    Article  CAS  PubMed  Google Scholar 

  133. Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019;20:2007–17.

    Article  CAS  PubMed  Google Scholar 

  134. Moradi H, Streja E, Vaziri ND. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients? Semin Dial. 2018;31(4):398–405.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  CAS  PubMed  Google Scholar 

  136. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  PubMed  CAS  Google Scholar 

  137. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2:547–55.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.

    PubMed  Google Scholar 

  140. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–71.

    Article  CAS  PubMed  Google Scholar 

  141. Elewa U, Fernández-Fernández B, Mahillo-Fernández I, Martin-Cleary C, Sanz AB, Sanchez-Niño MD, Ortiz A. PCSK9 in diabetic kidney disease. Eur J Clin Investig. 2016;46:779–86.

    Article  CAS  Google Scholar 

  142. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Ž, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Investigators. Effect of alirocumab on stroke in ODYSSEY OUTCOMES. Circulation. 2019;140:2054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, REDUCE-IT Investigators. REDUCE-IT USA: results from the 3146 patients randomized in the United States. Circulation. 2020;141:367–75.

    Article  PubMed  Google Scholar 

  144. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP, FOURIER Steering Committee and Investigators. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73:2961–70.

    Article  CAS  PubMed  Google Scholar 

  145. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O’Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54(2):280–90.

    Article  CAS  PubMed  Google Scholar 

  146. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.

    Article  CAS  PubMed  Google Scholar 

  147. Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with Type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    Article  CAS  PubMed  Google Scholar 

  149. Heerspink HJL. Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney. Nephrol Dial Transplant. 2019;34(12):2015–7.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019;8:e013389.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Dekkers CCJ, Gansevoort RT. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease? Nephrol Dial Transplant. 2020;35(Supplement_1):i33–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr. 2018;12:1117–23.

    Article  CAS  PubMed  Google Scholar 

  153. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.

    Article  CAS  PubMed  Google Scholar 

  154. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–17.

    Article  CAS  PubMed  Google Scholar 

  155. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35(2):274–82.

    Article  PubMed  PubMed Central  Google Scholar 

  156. AstraZeneca Press Release 30 March, 2020. www.astrazeneca.com/media-central/press-release/2020/farxiga-phase-iii-dapa-ckd-trial-will-be stopped-early. Accessed 30 Mar 2020.

  157. Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515–22.

    Article  CAS  PubMed  Google Scholar 

  158. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL. Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. Clin Med. 2019;8(6). pii: E779.

    Google Scholar 

  160. House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95:1304–17.

    Google Scholar 

  161. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8:e012356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. KDIGO Clinical practice guidelines on diabetes management in chronic kidney disease. (In press, 2020).

    Google Scholar 

  163. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37:2864–83.

    Article  PubMed  PubMed Central  Google Scholar 

  164. Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O, LEADER Trial Investigators. Safety of liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2020;15(4):465–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Cherney DZ, Tuttle KR. Liraglutide for the treatment of type 2 diabetes and safety in diabetic kidney disease: liraglutide and diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(4):444–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB, LEADER Trial Investigators. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75:1128–41.

    Article  CAS  PubMed  Google Scholar 

  167. Li J, Albajrami O, Zhuo M, Hawley CF, Paik JM. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020 June 9- [ePUB ahead of print].

    Google Scholar 

  168. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28.

    Article  PubMed Central  Google Scholar 

  169. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC, ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87:649–59.

    Article  PubMed  Google Scholar 

  170. Panduru NM, Nistor I, Groop PH, Van Biesen W, Farrington K, Covic A. Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrol Dial Transplant. 2017;32:591–7.

    Article  CAS  PubMed  Google Scholar 

  171. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RA, VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019;380:2215–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, Reda DJ, Emanuele NV, VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018;61(2):295–9.

    Article  PubMed  Google Scholar 

  173. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol. 2009;24(131):298–304.

    Article  Google Scholar 

  174. de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252.

    Article  PubMed  Google Scholar 

  176. Sinha AD, Agarwal R. Thiazide diuretics in chronic kidney disease. Curr Hypertens Rep. 2015;17:13.

    Article  PubMed  CAS  Google Scholar 

  177. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18:28–37.

    Article  CAS  PubMed  Google Scholar 

  178. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  179. Agarwal A, Cheung AK. Mineralocorticoid receptor antagonists in ESKD. Clin J Am Soc Nephrol. 2020;15(7):1047–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Ko GJ, Kalantar-Zadeh K, Goldstein-Fuchs J, Rhee CM. Dietary approaches in the management of diabetic patients with kidney disease. Nutrients. 2017;9: Pii. E824.

    Google Scholar 

  181. Kramer H. Diet and chronic kidney disease. Adv Nutr. 2019;10(Suppl_4):S367–79.

    Article  PubMed  PubMed Central  Google Scholar 

  182. Turner-McGrievy G, Mandes T, Crimarco A. A plant-based diet for overweight and obesity prevention and treatment. J Geriatr Cardiol. 2017;14:369–74.

    PubMed  PubMed Central  Google Scholar 

  183. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Grams ME, Coresh J, Rebholz CM. Plant-based diets and incident CKD and kidney function. Clin J Am Soc Nephrol. 2019;14:682–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Coresh J, Rebholz CM. Plant-based diets are associated with a lower risk of incident cardiovascular disease, cardiovascular disease mortality, and all-cause mortality in a general population of middle-aged adults. J Am Heart Assoc. 2019;8:e012865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Jia L, Jia Q, Yang J, Jia R, Zhang H. Efficacy of probiotics supplementation on chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43:1623–35.

    Article  CAS  PubMed  Google Scholar 

  186. Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019;73:309–15.

    Article  CAS  PubMed  Google Scholar 

  187. Chen CL, Chen NC, Wu FZ, Wu MT. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int. 2020;31(8):1507–16.

    Article  CAS  PubMed  Google Scholar 

  188. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94.

    Article  Google Scholar 

  190. Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019;20:309.

    Article  PubMed  PubMed Central  Google Scholar 

  191. Kim AJ, Lim HJ, Ro H, Ko KP, Han SY, Chang JH, Lee HH, Chung W, Jung JY. Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PLoS One. 2014;9:e104179.

    Article  PubMed  PubMed Central  Google Scholar 

  192. Stamellou E, Floege J. Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant. 2018;33:1683–9.

    Article  CAS  PubMed  Google Scholar 

  193. Krüger T, Floege J. Vitamin K antagonists: beyond bleeding. Semin Dial. 2014;27:37–41.

    Article  PubMed  Google Scholar 

  194. Glassock RJ. Anticoagulant-related nephropathy: it’s the real McCoy. Clin J Am Soc Nephrol. 2019;14:935–7.

    Article  PubMed  PubMed Central  Google Scholar 

  195. Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e202175.

    Article  PubMed  PubMed Central  Google Scholar 

  196. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384–92.

    Article  CAS  PubMed  Google Scholar 

  197. Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, Sánchez-Lozada LG, Kuwabara M, Borghi C, Johnson RJ. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15:767–75.

    Article  CAS  PubMed  Google Scholar 

  198. Maloberti A, Giannattasio C, Bombelli M, Desideri G, Cicero AFG, Muiesan ML, Rosei EA, Salvetti M, Ungar A, Rivasi G, Pontremoli R, Viazzi F, Facchetti R, Ferri C, Bernardino B, Galletti F, D’Elia L, Palatini P, Casiglia E, Tikhonoff V, Barbagallo CM, Verdecchia P, Masi S, Mallamaci F, Cirillo M, Rattazzi M, Pauletto P, Cirillo P, Gesualdo L, Mazza A, Volpe M, Tocci G, Iaccarino G, Nazzaro P, Lippa L, Parati G, Dell’Oro R, Quarti-Trevano F, Grassi G, Virdis A, Borghi C, Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Press Cardiovasc Prev. 2020;27(2):121–8.

    Article  PubMed  Google Scholar 

  199. Casiglia E, Tikhonoff V, Virdis A, Masi S, Barbagallo CM, Bombelli M, Bruno B, Cicero AFG, Cirillo M, Cirillo P, Desideri G, D’Elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Lippa L, Mallamaci F, Maloberti A, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Pontremoli R, Quarti-Trevano F, Rattazzi M, Rivasi G, Salvetti M, Tocci G, Ungar A, Verdecchia P, Viazzi F, Volpe M, Grassi G, Borghi C, Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020;38:412–9.

    Article  CAS  PubMed  Google Scholar 

  200. Steiger S, Ma Q, Anders HJ. The case for evidence-based medicine for the association between hyperuricaemia and CKD. Nat Rev Nephrol. 2020;16(7):422.

    Article  PubMed  Google Scholar 

  201. Su CY, Shen LJ, Hsieh S, Lin LY, Lin FJ. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94:1147–57.

    Article  PubMed  Google Scholar 

  202. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Febuxostat for cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40:1778–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Spertus JA, Jones PG, Maron DJ, O’Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE Jr, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB, ISCHEMIA Research Group. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med. 2020;382(15):1408–19. https://doi.org/10.1056/NEJMoa1916370.

    Article  PubMed  PubMed Central  Google Scholar 

  204. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS, ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382(17):1608–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C, Conference Participants. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39:2314–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  206. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:5–14.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, University of California at Irvine Medical Center, Irvine, CA, USA

    Robin H. Lo

  2. Department of Medicine, Geffen School of Medicine at UCLA, Laguna Niguel, CA, USA

    Richard J. Glassock

Authors
  1. Robin H. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Glassock
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, Irvine, CA, USA

    Nathan D. Wong

  2. Division of Cardiovascular Medicine, University of California, Davis, Sacramento, CA, USA

    Ezra A. Amsterdam

  3. Cicarrone Center for the Prevention of Cardiovascular Disease, John Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lo, R.H., Glassock, R.J. (2021). Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. In: Wong, N.D., Amsterdam, E.A., Toth, P.P. (eds) ASPC Manual of Preventive Cardiology. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-56279-3_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56279-3_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56278-6

  • Online ISBN: 978-3-030-56279-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation